Jeito Capital, an independent private equity fund dedicated to biopharma, has announced the final close of its second fund Jeito II, exceeding its €1bn target at US$1.2bn. With this new fund, Jeito has tripled its AUM to €1.6bn, following the closing in 2021 of Jeito I at US$630m.
“This record fundraising is a collective success, reflecting the dedication and expertise of the entire Jeito team, the talent of its portfolio companies’ managers and the trust of our investors,” said Dr Rafaèle Tordjman, founder and CEO. “It is also a strong signal for the European biopharma ecosystem, demonstrating the growing conviction that European companies can drive major therapeutic innovation and significant economic benefits with the appropriate access to financial and strategic resources.”
The fund attracted international investors from a diversified base across Europe, North America and Asia, including sovereign and public funds, pharmaceutical and corporate investors, insurance companies, pension funds, family offices, foundations, endowments and banks.
It will continue the strategy established with Jeito I: backing 15 to 20 of the most promising clinical stage biopharma companies, primarily in Europe, targeting therapies for severe diseases with high unmet needs and accelerating the development path and future market access.
“Jeito II continues a disciplined and proven strategy built around a clear conviction: some of the most compelling opportunities in Biopharma lie at the intersection of scientific excellence, strong unmet medical need and growing demand for differentiated innovation,” said managing partner Sabine Dandiguian. “In this environment, value creation requires both selectivity and continuity, backing the best companies, at the right time, with the right level of capital and expertise.”
The fundraising enables Jeito to increase the average size of future investments in portfolio companies up to €150m. It has already deployed capital from the latest fund in therapeutic areas with strong demand: obesity, reproductive medicine, oncology, autoimmune and inflammatory diseases, neurology and cardio-metabolic diseases.
